Carregant...
Targeting EGFR and ALK in NSCLC: current evidence and future perspective
The advent of molecular therapy targeting specific driver oncogenes has dramatically changed the prognosis of a subset of NSCLC, dilating survival and improving the quality of life of patients with advanced disease. Two of the major targets for treatment with receptor TKIs are the activated mutated...
Guardat en:
| Publicat a: | Lung Cancer Manag |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Medicine Ltd
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310340/ https://ncbi.nlm.nih.gov/pubmed/30643552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2016-0005 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|